慢性誘導性蕁麻疹治療薬の世界市場:疫学予測

◆英語タイトル:Chronic Inducible Urticaria Epidemiology Forecast to 2030
◆商品コード:DELV20JU182
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(182名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Chronic Inducible Urticaria – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted chronic inducible urticaria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030
Chronic Inducible Urticaria: Understanding
The DelveInsight’s chronic inducible urticaria (CIndU) epidemiology report gives a thorough understanding of the CIndU by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for CIndU in the US, Europe, and Japan. Moreover, the report covers the detailed information of the chronic inducible urticaria epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight
This section encompassing chronic inducible urticaria (CIndU) epidemiology provides insights about historical and current patient pool and forecasted trend for every seven major countries. The CIndU epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation
The chronic inducible urticaria epidemiology covered in the report provides historical as well as forecasted CIndU epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
The chronic inducible urticaria (CIndU) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The CIndU report and model provide an overview of the global trends of CIndU in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report provides insight into the historical and forecasted patient pool of CIndU in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of chronic inducible urticaria.
The report provides the segmentation of the Chronic Inducible Urticaria epidemiology
Report Highlights
11-year Forecast of Chronic Inducible Urticaria Epidemiology
7MM Coverage
Diagnosed prevalent cases of CU
Diagnosed prevalent cases of CIndU
Prevalence of chronic inducible urticaria by types
KOL – Views:
We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM concerning the patient population pertaining to chronic inducible urticaria (CIndU)?
What are the key findings pertaining to the chronic inducible urticaria (CIndU) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
What would be the total number of patients of chronic inducible urticaria (CIndU) across the 7MM during the forecast period (2017–2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
What is the disease risk, burden and unmet needs of chronic inducible urticaria (CIndU)?
What are the currently available treatments of chronic inducible urticaria (CIndU)?
Reasons to buy
The chronic inducible urticaria (CIndU) Epidemiology report will allow the user to:

Develop business strategies by understanding the trends shaping and driving the global chronic inducible urticaria (CIndU) market.
Quantify patient populations in the global chronic inducible urticaria (CIndU) market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic inducible urticaria (CIndU) therapeutics in each of the markets covered
Understand the magnitude of chronic inducible urticaria (CIndU) population by its epidemiology
The chronic inducible urticaria (CIndU) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1 Key Insights

2 Executive Summary of Chronic Inducible Urticaria

3 SWOT Analysis for Chronic Inducible Urticaria

4 Chronic Inducible Urticaria Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2017

4.2 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2030

5 Chronic Inducible Urticaria Market Overview at a Glance

5.1 Market Share (%) Distribution of Chronic Inducible Urticaria in 2017

5.2 Market Share (%) Distribution of Chronic Inducible Urticaria in 2030

6 Disease Background and Overview

6.1 Introduction

6.2 Types

6.3 Pathophysiology

6.4 Clinical features

6.5 Diagnosis

6.6 Clinical manifestation

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Total Prevalent Population of CIndU in 7MM

7.3 Assumptions and Rationale: 7MM

8 Country-wise Epidemiology of Chronic Inducible Urticaria

8.1 The United States

8.1.1 Diagnosed Prevalent cases of CU in the United States

8.1.2 Diagnosed Prevalent cases of CIndU in the United States

8.1.3 Prevalence of Chronic Inducible Urticaria by Types in the United States

8.2 EU5

8.2.1 Germany

8.2.2 France

8.2.3 Italy

8.2.4 Spain

8.2.5 The United Kingdom

8.3 Japan

8.3.1 Diagnosed Prevalent cases of CU in Japan

8.3.2 Diagnosed Prevalent cases of CIndU in Japan

8.3.3 Prevalence of Chronic Inducible Urticaria by Types in Japan

9 Treatment and Management

9.1 Guidelines

10 Case Study

10.1 Severe cold urticaria including anaphylaxis

10.2 Severe symptomatic dermographism (urticaria factitia)

11 Patient Journey

12 Unmet Needs

13 Appendix

13.1 Report Methodology

14 DelveInsight Capabilities

15 Disclaimer

16 About DelveInsight

 Table 1: Summary of CIndU Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total cases of Chronic Inducible Urticaria in 7MM (2017–2030)

Table 3: Diagnosed Prevalent cases of CU in the United States (2017–2030)

Table 4: Diagnosed Prevalent cases of CIndU in the United States (2017–2030)

Table 5: Prevalence of Chronic Inducible Urticaria by Types in the United States (2017–2030)

Table 6: Diagnosed Prevalent cases of CU in Germany (2017–2030)

Table 7: Diagnosed Prevalent cases of CIndU in Germany (2017–2030)

Table 8: Prevalence of Chronic Inducible Urticaria by Types in Germany (2017–2030)

Table 9: Diagnosed Prevalent cases of CU in France (2017–2030)

Table 10: Diagnosed Prevalent cases of CIndU in France (2017–2030)

Table 11: Prevalence of Chronic Inducible Urticaria by Types in France (2017–2030)

Table 12: Diagnosed Prevalent cases of CU in Italy (2017–2030)

Table 13: Diagnosed Prevalent cases of CIndU in Italy (2017–2030)

Table 14: Prevalence of Chronic Inducible Urticaria by Types in Italy (2017–2030)

Table 15: Diagnosed Prevalent cases of CU in Spain (2017–2030)

Table 16: Diagnosed Prevalent cases of CIndU in Spain (2017–2030)

Table 17: Prevalence of Chronic Inducible Urticaria by Types in Spain (2017–2030)

Table 18: Diagnosed Prevalent cases of CU in the United Kingdom (2017–2030)

Table 19: Diagnosed Prevalent cases of CIndU in the United Kingdom (2017–2030)

Table 20: Prevalence of Chronic Inducible Urticaria by Types in the United Kingdom (2017–2030)

Table 21: Diagnosed Prevalent cases of CU in Japan (2017–2030)

Table 22: Diagnosed Prevalent cases of CIndU in Japan (2017–2030)

Table 23: Prevalence of Chronic Inducible Urticaria by Types in Japan (2017–2030)

List of Figures

 Figure 1: SWOT Analysis

Figure 2: The Inflammation of Mast Cells in Chronic Inducible Urticaria

Figure 3: The Inflammation of Mast Cells in Chronic Inducible Urticaria

Figure 4: Recommended diagnostic algorithm for chronic urticaria

Figure 5: Total cases of Chronic Inducible Urticaria in 7MM (2017–2030)

Figure 6: Diagnosed Prevalent cases of CU in the United States (2017–2030)

Figure 7: Diagnosed Prevalent cases of CIndU in the United States (2017–2030)

Figure 8: Prevalence of Chronic Inducible Urticaria by Types in the United States(2017–2030)

Figure 9: Diagnosed Prevalent cases of CU in Germany (2017–2030)

Figure 10: Diagnosed Prevalent cases of CIndU in Germany (2017–2030)

Figure 11: Prevalence of Chronic Inducible Urticaria by Types in Germany(2017–2030)

Figure 12: Diagnosed Prevalent cases of CU in France (2017–2030)

Figure 13: Diagnosed Prevalent cases of CIndU in France (2017–2030)

Figure 14: Prevalence of Chronic Inducible Urticaria by Types in France(2017–2030)

Figure 15: Diagnosed Prevalent cases of CU in Italy (2017–2030)

Figure 16: Diagnosed Prevalent cases of CIndU in Italy (2017–2030)

Figure 17: Prevalence of Chronic Inducible Urticaria by Types in Italy(2017–2030)

Figure 18: Diagnosed Prevalent cases of CU in Spain (2017–2030)

Figure 19: Diagnosed Prevalent cases of CIndU in Spain (2017–2030)

Figure 20: Prevalence of Chronic Inducible Urticaria by Types in Spain(2017–2030)

Figure 21: Diagnosed Prevalent cases of CU in the United Kingdom (2017–2030)

Figure 22: Diagnosed Prevalent cases of CIndU in the United Kingdom (2017–2030)

Figure 23: Prevalence of Chronic Inducible Urticaria by Types in the United Kingdom(2017–2030)

Figure 24: Diagnosed Prevalent cases of CU in Japan (2017–2030)

Figure 25: Diagnosed Prevalent cases of CIndU in Japan (2017–2030)

Figure 26: Prevalence of Chronic Inducible Urticaria by Types in Japan(2017–2030)

Figure 27: Recommended treatment algorithm for Chronic Urticaria

Figure 28: Patient Journey Chronic Inducible Urticaria

Figure 29: Unmet Needs

Figure 30: Market Drivers

Figure 31: Market Barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[慢性誘導性蕁麻疹治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆